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We evaluated the in vitro effects of IL-12, alone and in associ- In this study, we investigated the effect of IL-12, alone and
ation with IL-2 on MDS bone marrow and peripheral blood cells. in association with IL-2, on PB and BM NK cells, lymphocyte
Thirty-six patients and 14 healthy subjects were studied. Natu- phenotype, cytokine release and BM clonogenic activity in
ral killer-activity (NK-a) levels and lymphocyte immunopheno-
MDS patients, with the aim of exploring further the impact oftypes were determined in fresh bone marrow (BMMNC) and
the cytokine network on the proliferation and differentiationperipheral blood mononuclear cells (PBMNC), which then were
resuspended in medium containing IL-2, IL-12 or IL-2 1 IL-12 of MDS cells.
for 7 days. Re-evaluation of NK-a levels, lymphocyte immuno-
phenotypes, clonogenic activity and cytokine release showed
that, unlike IL-2, IL-12 did not significantly increase NK-a or
Materials and methodsCD32/561 cell levels in either bone marrow or peripheral blood;
IL-2 1 12 led to a significant increase that fell between the
values reached by each cytokine alone. IL-2 1 12 and, although Patients
to a lesser extent, also IL-12 alone induced the release of large
amounts of g-IFN and a-TNF. In addition, the number of clus-
BM and PB cells were obtained from 36 patients (M/F = 19/17)ters particularly decreased in the samples treated with IL-2 1
with de novo MDS and 14 normal bone marrow and peri-12 and IL-12 alone. Clonogenic activity was not modified after
pheral blood donors, after they had given their informed con-stimulation with any of the treatment. These data suggest that
IL-12 induces the release of inhibitory cytokines in normal as sent. The median age of the patients was 73.5 years (range
well as MDS cells and that it could be used in patients with 21–88), and they were classified according to FAB criteria as
elevated bone marrow blastosis. being affected by refractory anemia (RA n = 10), refractoryKeywords: myelodysplastic syndromes; interleukin-12; interleukin-
anemia with ring sideroblasts (RARS n = 11), refractory anemia2; NK activity; clonogenic activity
with excess of blasts (RAEB n = 14) and refractory anemia with
excess of blasts in transformation (RAEB-t n = 1). Their clinical
characteristics are summarized in Table 1. For the purposesIntroduction
of this study, we decided to define RA + RARS as low-risk (LR)
MDS and RAEB + RAEB-t as high-risk (HR) MDS. Patients withSevere peripheral blood cytopenia, together with bone mar-
CMML were excluded from the study because of the smallrow hypercellularity and dysplasia are frequently the hallmark
number who had been under our observation.of myelodysplastic syndromes (MDS).1–5 Although it has been
established that these hematological disorders arise from the
clonal expansion of the progeny of an aberrant pluripotential
Cell preparationstem cell,6–8 little it is known about their etiology and patho-
genesis.
The PB and BM samples were collected in preservative-freeMorphological involvement of the myeloid lineage is
heparin. The mononuclear cells (MNC) were separated byalways observed in MDS, whereas there is evidence of peri-
gradient centrifugation using Ficoll Lymphoprep (Nicomedpheral lymphopenia and functional of B and T cell abnormali-
Pharma, Oslo, Norway) and then washed twice with phos-ties only in some cases. Attention has recently been directed
phate-buffered saline.to the role of NK cells and immunoregulatory cytokines in the
genesis of MDS. A number of studies have shown that peri-
pheral blood natural killer-activity (NK-a) was decreased in
MDS patients,9–11 even though these observations do not BM and PB liquid cultures
necessarily imply the clonal involvement of NK cells.12,13
IL-12 is a heterodimeric cytokine physiologically produced The PBMNC were suspended at a concentration of 1 × 106
by phagocytes, B lymphocytes and other antigen-presenting cells/ml in RPMI 1640 (Life Technologies, Gaithersburg, MD,
cells (APC).14–16 It has been shown to cause the proliferation USA) with 10% human AB serum (Flow ICN Biomedicals,
of activated T and NK cells, to enhance the lytic activity of NK Costa Mesa, CA, USA), whereas the BMMNC were resus-
cells and to induce the production of antileukemic cytokines, pended at the same concentration in IMDM (Life
particularly g-IFN.16–20 In a previous study, we demonstrated Technologies) with 10% FCS (Hyclone Laboratories, Logan,
that the defective bone marrow (BM) and peripheral blood UT, USA). RhIL-12 (Sigma-Aldrich, Milan, Italy) at a concen-
(PB) NK-activity in MDS patients can be restored in vitro by tration of 0.1 ng/ml with or without RhIL-2 (Proleukin; Cetus
the addition of another immunoregulatory cytokine, IL-2.21 Corporation, Emeryville, CA, USA) 500 U/ml was added to
the liquid cultures and then incubated at 37°C in 5% CO2 for
a week. The cells were then washed twice in PBS and the
viability (always more than 90%) of the BM and PB cells wasCorrespondence: A Cortelezzi, Servizio di Ematologia, Via Francesco
evaluated by the Trypan blue exclusion test at the end ofSforza, 35, Ospedale Maggiore, 20122 Milano, Italy
Received 23 October 1996; accepted 26 June 1997 the culture.
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1727Table 1 Characteristics of the patient group
Patient Sex/Age FAB Blastsa Karyotype
1 F/81 AR 2.75 46, XX
2 M/76 AR 3 46, XY
3 M/58 AR 1.75 47, XY, +8
4 M/59 AR 3.75 46, XY
5 M/89 AR 4.75 46, XY
6 F/57 AR 3 46, XX
7 F/70 AR 2 46, XX
8 F/63 AR 4.25 complex karyotype
9 F/88 AR 2 46, XX, inv 9
10 M/21 AR 1.5 46, XY
11 F/62 ARS 3.5 46, XX
12 M/59 ARS 4.75 46, XY
13 F/64 ARS 3.5 46, XX
14 M/69 ARS 4.5 46, XY
15 F/33 ARS 1.25 46, XX
16 M/72 ARS 2.5 46, XY
17 M/77 ARS 2 46, XY
18 M/84 ARS 3 46, XY
19 M/61 ARS 4.25 46, XY
20 F/57 ARS 1 46, XX
21 M/80 ARS 4.75 46, XY
22 F/82 AREB 7 45, XX, −7
23 M/69 AREB 17.75 46, XY
24 F/74 AREB 5.75 47, XX, +8, 5q−, 12q−
25 F/64 AREB 19.75 46, XX, 3q−
26 F/75 AREB 5.75 46, XX/ 47, XX, +8
27 M/60 AREB 9 NE
28 F/75 AREB 8 46, XX, 5q−
29 M/72 AREB 9 NE
30 F/70 AREB 5.75 47, XX, +13
31 M/57 AREB 6 46, XY
32 M/67 AREB 6.5 48, XY, +8, +6
33 F/54 AREB 10 46, XX
34 M/45 AREB 8.75 46, XY, 5q−
35 F/53 AREB 10.25 46, XX, 5q−
36 M/66 AREB-t 25.5 46, XY
aBM blasts at the time of the study.
NE, not evaluated.
NK-activated cell assay Lymphocyte phenotype analysis
Before testing NK activity, we determined the percentage of
The PB and BM mononuclear cells were labeled with anti-lymphocytes in the PBMNC and BMMNC in order to confirm
CD3Fitc and CD56PE (Leu-4, Leu-3a+3b, Leu-2a, Leu-12;the effector/target ratio. A 4 h 51Cr release assay was then used
Becton Dickinson Immunocytometry System, San Jose, CA,with K562 cells as the target. The target cells were labelled
USA), and analyzed using a flow cytometer (FACSCAN,with 100 mCi of Na2 51CrO4 (Amersham, Arlington Heights, Becton Dickinson).IL, USA) per 1 × 106 cells for 1 h at 37°C, and used at a final
concentration of 5 × 103/well. The effector cells were added
to 96-well microculture plates (Cel-Cult, Sterilin Limited, Fel-
tham, UK) and incubated at different effector/target cell ratios
(50:1, 25:1, 12.5:1, 6.25:1) for 4 h at 37°C in 5% CO2. Radio- Release of GM-CSF, gIFN and aTNF in theactivity was measured in a gamma-counter (Cobra Auto- supernatant of BM liquid culturesGamma, PACKARD, Canberra Company, IL, USA), and spe-
cific cytotoxicity was calculated from the mean counts per
minute (c.p.m.) of three replicate samples using the follow- The supernatants obtained by spinning the contents of the BM
ing formula: liquid cultures at the end of the culture time were stored at
−20°C until used, and then investigated for their GM-CSF, g-
% 51Cr release =
exp. c.p.m. − spont. rel. c.p.m.
max c.p.m. − spont. rel. c.p.m. IFN and a-TNF content by means of commercially available
immunoenzymatic assay kits (Medgenix Diagnostic, Fleurus,
Belgium). Minimum detectable concentratium (MDC) was 3The spontaneous release value was always less than 10% of
total radioactivity. pg/ml for a-TNF and GM-CSF, and 0.03 IU/ml for g-IFN.
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1728 Agar colony assay (CFU-GM) respectively), although a significant increase was observed
between the cultured controls and the IL-12-stimulated BM
and PB cells. After incubation with IL-2, a significant (P ,Clonogenic potential after incubation with IL-12 ± IL-2 was
evaluated by means of agar colony assay (CFU-GM). 1 × 106 0.01) increase in NK-a was observed (average specific peri-
pheral and bone marrow lysis was 51.7 and 36.9%,cells/ml in IMDM were cultured in 1 ml of a mixture contain-
ing 20% FCS, 3% agar, rhGM-CSF 200 U/ml (Genzyme, Cam- respectively), which was only slightly lower than that seen in
the IL-2-stimulated normal controls. The association of thebridge, MA, USA) and IL-3 100 U/ml (Genzyme). The plates
were incubated in humidified air with 5% CO2 at 37°C for 2 two cytokines led to an increase in NK-a that fell between the
values reached by each of them alone (average percent spe-weeks. The aggregates containing .50 cells were scored as
colonies, whereas those containing ,50 cells were scored as cific peripheral and bone marrow lysis was 40.2 and 22.7%,
respectively). No statistically significant differences wereclusters. All of the cultures were set up in triplicate.
observed between LR and HR groups (Figure 2a and b).
Statistical analysis
The Wilcoxon-matched-pairs-signed-rank’s test was used to Lymphocyte immunophenotypeevaluate the within-group differences, and the Mann–Whitney
test for the differences between groups. A P value of ,0.05
was considered to be statistically significant. No difference was observed in the immunophenotypes of the
MDS samples with and without the addition of IL-12 after 7
days of culture. As already observed,16 in comparison with
Results cultured controls, a significant increase in peripheral blood (P
, 0.05) and bone marrow (P , 0.01) CD3−/56+ cells occurred
In a preliminary phase of the study, we evaluated the effect after the addition of IL-2 alone (Figure 3a and b). Moreover,
of IL-12 on NK-a in PB mononuclear cells taken from healthy the association of IL-2 + IL-12 increased the percentage of
donors at different times of incubation and at various concen- CD3−/CD56+ cells to values falling between those reached by
trations. The dose–response curve is shown in Figure 1. We each of them alone. No statistically significant differences
can assume that IL-12 0.1 U/ml for 1 week better stimulates were observed between LR and HR groups.
NK-a, although not significantly so in comparison with the
basal value. As far as IL-2, GM-CSF and IL-3 are concerned,
we used the same dosages as those used in our previous
study.21 Once again, we also evaluated the sequential stimu-
lus IL-2 → IL-12 (IL-2 was added at t = 0, IL-12 after 24 h),
but we did not observe any increase in NK-a with respect to
the sample treated with a simultaneous stimulus (data not
shown).
NK activity
As already observed in a previous study,21 baseline peripheral
and bone marrow NK-a in the MDS patients was lower than
in the normal subjects: the average specific lysis in peripheral
blood was 14.6% in MDS patients and 38.6% in normal con-
trols (P , 0.01), whereas bone marrow NK-a was 5.3% in
MDS patients and 7.2% in donors (NS). IL-12 stimulation did
not induce any increase in NK-a in peripheral and bone mar-
row MDS cells with respect to pre-cultured controls (average
specific peripheral and bone marrow lysis was 13.3 and 8%,
Figure 2 Pre- and post-IL-12 and/or IL-2 stimulation on PB (a) and
BM (b) NK-activity (± s.e.) in normals and MDS patients. Percentage
of specific lysis of K562 cells at an E:T ratio of 50:1 for PB and ofFigure 1 Effect of IL-12 on NK-a of normal PB cells at time 0 and
after 1, 2, 3 and 7 days. 25:1 for BM. *P , 0.05; **P , 0.01.
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Figure 3 CD3−/56+ percentage (± s.e.) of stimulated MDS peri-
pheral blood (a) and bone marrow (b) cells in comparison with basal
and untreated samples (control). Statistical comparison carried out
between controls and stimulated samples. *P , 0.05; **P , 0.01.
Cytokine release
GM-CSF, g-IFN and a-TNF release in the supernatant of the
MDS bone marrow liquid cultures significantly increased after
incubation with IL-12, IL-2 and IL-2 + 12. IL-12 alone
increased g-IFN and a-TNF, but not GM-CSF values to a
greater extent than IL-2 (mean values: 48.8 vs 10.5 IU/ml for
g-IFN, 1883.1 vs 655.3 pg/ml for a-TNF, 142.8 vs 168.9 pg/ml
for GM-CSF) (Figure 4a, b and c). In particular, the IL-2 + 12
association increased GM-CSF and a-TNF values in an addi-
tive manner, whereas the effect of IL-2 + 12 on g-IFN was
synergistic (290-fold with respect to the basal).
Clonogenic assay
The 7-days preincubation with IL-12 in the liquid culture did
Figure 4 GM-CSF (a), a-TNF (b) and g-IFN (c) in supernatants (±not induce any modification in the number of CFU-GM (mean s.e.) of MDS bone marrow cultures after incubation with IL-12 and/or
baseline CFU-GM/ml = 33; mean IL-12 CFU-GM/ml = 25.8), IL-2. *P , 0.05; **P , 0.01.
but the number of clusters decreased (although not
significantly) after the addition of the cytokines to the medium
with respect to the untreated control (IL-2 + 12.12.2) (Figure case, to a lesser extent than optimal doses of IL-2.14 It is also
known that IL-12 releases into the culture medium large5). Unlike in our previous study,16 we did not observe any
significant increase in the number of CFU-GM after incu- amounts of g-IFN,16–20 a cytokine with potent antiproliferative
activity. These characteristics, together with the fact that NK-bation with IL-2.
a is reduced in MDS patients, prompted us to evaluate the in
vitro effects of IL-12 on the bone marrow and peripheral blood
cells of such patients.Discussion
In our in vitro system, IL-12 induced a modest but non-
significant increase in NK-a in both normal and myelodysplas-It is well known that IL-12 is capable of stimulating the cyto-
toxic activity of both T and NK cells, although, in the latter tic cells in comparison with basal values. In contrast, the use
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kines in amounts similar to those secreted by normal control
cells.
In our in vitro system, we did not observe any increase in
the number of CFU-GM prepared after 7 days of incubation
with IL-2, IL-12 and IL-2 + 12 in comparison with control
values. The non-significant increase in clonogenic activity
after the addition of IL-2 appears to contradict our previous
results and may be related to the longer time of incubation:
the amount of inhibitory cytokines released in the supernatant
after 7 days was much higher than that observed after the 24-
and 72-h incubation periods used in our previous study. Fur-
thermore, we did not observe any increase in the number of
immature myeloid cells after incubation with IL-2, IL-12 and
IL-2 + 12 when the centrifuged cells were morphologically
analyzed (data not shown). Finally, we observed a progress-
Figure 5 MDS bone marrow clonogenic activity (± s.e.) after incu- ive, although not significant, decrease in the absolute number
bation with IL-12 and/or IL-2 in comparison with untreated control. of clusters after incubation with IL-2, IL-12 and IL-2 + 12 in
comparison with control samples (respectively: 13.9
clusters/ml, 11 clusters/ml, 10.6 clusters/ml and 14.8
clusters/ml). The colony/cluster ratio was 2.5 in the controls,of IL-2 led to a marked increase in BM and PB cell NK-a in
the MDS patients that was only slightly lower than that which increased to 2.8 after stimulation with IL-2, and to 2.7
after stimulation with IL-12. After double stimulation (IL-2 +observed in normal subjects (average specific lysis of 36.9 vs
44.8% and 51.7 vs 61.4%, respectively). Unlike Ogata et al,22 IL-12), the ratio was 2.4 which may be explained by the
inhibitory action of g-IFN on normal myelopoiesis,29 as its lev-we did not observe any synergistic activity between IL-2 and
IL-12 in the enhancement of NK-a in either normal or MDS els were considerably higher in the supernatant. We can
therefore conclude that neither IL-2 nor IL-12 stimulate thesubjects; however, this may be due to our different IL-2 and
IL-12 doses and culture times. Gately et al23 observed that the proliferation of the leukemic component. It is known that IL-
12, together with other cytokines such as IL-3 and SCF,30–32association of IL-12 and IL-2 in culture for 4 days may lead
to increases or decreases in LAK activity, depending on the belongs to the group of early-acting cytokines that acts on
hemopoietic progenitors. Further studies are necessary toquantity of IL-12. Furthermore, other studies24 have shown
that the association of IL-12 + IL-2 in culture for 18 h increases evaluate whether IL-12 and other early-acting cytokines may
stimulate clonal and non-clonal stem cells in MDS.cytolytic activity only marginally in comparison with optimal
doses of IL-2. Our study shows that IL-12 does not induce a significant
increase in NK activity or in the number of CD3−/CD56+ cellsWe did not observe any increase in the number of
CD3−/CD56+ cells after IL-12 stimulation in either the MDS in MDS subjects, but it is particularly active in the release of
antitumoral cytokines, especially g-IFN. This last findingpatients or controls, which was not the case after stimulation
with IL-2; as for NK-a, the increase after double stimulation makes it possible to hypothesize the use of IL-12 particularly
in clinical studies involving patients with a high bone marrowwith IL-12 + IL-2 fell between the values obtained using the
two cytokines individually. This result also confirms the data blastic component.33 In addition to having a potent antitumo-
ral effect,34 g-IFN may also play a protective role against intra-published in the literature concerning normal control subjects
in whom IL-2 induces CD3−/CD56+ proliferation, whereas IL- cellular pathogen infections35–37 as a result of the known g-
IFN-driven macrophage activation. Finally, IL-12 may play a12 appears to have no effect on the proliferation of the non-
activated NK compartment. Furthermore, although IL-12 is further and important role in resistance to infection by increas-
ing the cell-mediated response that depends on the Th1 cellcapable of inducing activated T cell proliferation, it mainly
inhibits the IL-2-induced proliferation of NK cells.25 This effect development that is regulated by IL-12 itself.23,38 The double
stimulus of IL-2 + IL-12 may potentiate not only the release ofis at least partially indirect, and depends on the a-TNF pro-
duction induced by IL-12, as can be seen by the fact that anti- antileukemic cytokines but also the release of GM-CSF, which
could enhance the proliferation of residual normal hemopo-TNF antibodies are capable of restoring approximately 70%
of the IL-2-induced proliferation.23,25–27 ietic progenitors. The potential importance of these possible
effects would justify further and more specific investigations.However, in our in vitro system, IL-12 led to a dramatic
increase in g-INF and a-TNF in the cell culture medium of
both normal subjects and MDS patients. In particular, in the
MDS samples, IL-12 proved to be a more potent inducer of Acknowledgements
cytokines with antitumoral activity than IL-2, whereas the
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